These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8857550)

  • 1. Mycophenolate mofetil--clinical and experimental experience.
    Pirsch JD; Sollinger HW
    Ther Drug Monit; 1996 Aug; 18(4):357-61. PubMed ID: 8857550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
    Allison AC; Eugui EM
    Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
    Behrend M
    BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?
    Cox VC; Ensom MH
    Ther Drug Monit; 2003 Apr; 25(2):137-57. PubMed ID: 12657908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil and its mechanisms of action.
    Allison AC; Eugui EM
    Immunopharmacology; 2000 May; 47(2-3):85-118. PubMed ID: 10878285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
    Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
    Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil: An update.
    Villarroel MC; Hidalgo M; Jimeno A
    Drugs Today (Barc); 2009 Jul; 45(7):521-32. PubMed ID: 19834629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
    Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
    Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.
    Goldsmith D; Carrey EA; Edbury S; Smolenski RT; Jagodzinski P; Simmonds HA
    Clin Sci (Lond); 2004 Jul; 107(1):63-8. PubMed ID: 14723604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.